2,514 Danaher Corporation $DHR Shares Bought by Covenant Asset Management LLC

Covenant Asset Management LLC grew its position in shares of Danaher Corporation (NYSE:DHR) by 94.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,176 shares of the conglomerate’s stock after purchasing an additional 2,514 shares during the period. Covenant Asset Management LLC’s holdings in Danaher were worth $1,147,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Marquette Asset Management LLC grew its holdings in Danaher by 192.1% during the 3rd quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 73 shares in the last quarter. N.E.W. Advisory Services LLC purchased a new stake in Danaher during the 2nd quarter worth $25,000. Main Street Group LTD acquired a new position in Danaher in the 1st quarter worth $25,000. Field & Main Bank acquired a new position in Danaher in the 2nd quarter worth $29,000. Finally, Evolution Wealth Management Inc. lifted its holdings in Danaher by 208.0% in the 1st quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock worth $29,000 after buying an additional 104 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on DHR. Morgan Stanley upped their price objective on shares of Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research report on Monday. UBS Group assumed coverage on Danaher in a research report on Wednesday, September 9th. They set a “buy” rating and a $250.00 target price on the stock. Barclays boosted their price target on Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Royal Bank Of Canada increased their price target on Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Finally, Wells Fargo & Company lowered their price objective on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 22nd. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $235.41.

Danaher Stock Up 0.8%

Shares of NYSE:DHR opened at $224.65 on Thursday. The firm has a market cap of $157.93 billion, a PE ratio of 39.90, a price-to-earnings-growth ratio of 2.80 and a beta of 0.76. The company has a fifty day simple moving average of $212.92 and a 200 day simple moving average of $195.39. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The firm had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm’s revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.77 EPS. On average, equities research analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.